Zevra Therapeutics, Inc.
ZVRA
$7.98
-$0.23-2.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.64M | -91.99M | -105.51M | -89.66M | -66.81M |
| Total Depreciation and Amortization | 6.57M | 6.48M | 6.39M | 5.53M | 3.97M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.24M | 37.13M | 36.10M | 18.93M | 3.15M |
| Change in Net Operating Assets | -19.19M | -13.34M | -6.64M | -4.37M | 3.63M |
| Cash from Operations | -46.21M | -61.72M | -69.67M | -69.57M | -56.06M |
| Capital Expenditure | -312.00K | -99.00K | -- | -72.00K | -244.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -30.40M | -30.40M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.04M | -26.31M | -22.16M | 24.37M | 11.44M |
| Cash from Investing | -14.35M | -26.41M | -22.16M | -6.11M | -19.21M |
| Total Debt Issued | 0.00 | 60.07M | 60.07M | 63.70M | 89.70M |
| Total Debt Repaid | -372.00K | -43.50M | -43.13M | -47.86M | -47.66M |
| Issuance of Common Stock | 68.92M | 68.02M | 67.26M | 72.57M | 7.86M |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -2.09M | -2.09M | -2.09M | -2.09M |
| Cash from Financing | 68.55M | 82.50M | 82.11M | 86.32M | 47.81M |
| Foreign Exchange rate Adjustments | 466.00K | 127.00K | 454.00K | 132.00K | 521.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.45M | -5.51M | -9.26M | 10.77M | -26.94M |